Terns reports on TERN-701 CML drug trial progress

FOSTER CITY, Calif. – Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a biopharmaceutical company focused on developing small molecule medicines to treat serious diseases, including oncology, announces the Phase 1 development of TERN-701 The latest results of the study. The study is currently ongoing and is designed to examine the pharmacokinetics, safety and tolerability of TERN-701 in healthy volunteers.

TERN-701, an oral, potent, allosteric BCR-ABL inhibitor, is a novel therapy for the treatment of chronic myelogenous leukemia (CML) designed to provide better efficacy than traditional active site tyrosine kinase inhibitors (TKIs). ) greater efficacy and safety. Interim study results suggest that TERN-701 can be taken once daily with or without food, which may be more effective than the current allosteric BCR-ABL inhibitor asciminib, which requires fasting and twice-daily dosing. Significant advantages.

The Phase 1 trial enrolled 32 healthy volunteers at doses ranging from 20 mg to 160 mg, divided into four dose groups. The results showed no clinically significant changes in clinical laboratory data, vital signs or electrocardiogram parameters, and the pharmacokinetic characteristics were consistent with those observed in similar studies conducted in China by Tuozhen Biotech's partner Hansoh Pharmaceuticals.

An important finding of the study was that at the 80 mg dose, there was no significant difference in plasma exposure of TERN-701 whether taken with a high-fat meal or on an empty stomach. This supports the potential for flexible dosing regimens for patients.

The CARDINAL trial is a global Phase 1 clinical trial evaluating the safety, pharmacokinetics and efficacy of TERN-701 in patients with previously treated CML. Interim data from the initial cohort are expected to be released in the second half of 2024.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads

CML is a cancer in which the bone marrow produces an excess of white blood cells. In the United States, it is considered an orphan disease, with 9,280 new cases expected in 2024. .

The development of TERN-701 is part of Terns Pharmaceuticals' broader mission to address serious diseases through its portfolio of small molecule product candidates. The company plans to present data from the Healthy Volunteers study at an upcoming scientific meeting.

Investment Professional Insights

As Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) makes significant progress in the development of TERN-701 to treat chronic myelogenous leukemia, investors must consider the company's financial health and market performance. Tuozhen Pharmaceuticals has a market capitalization of $329.84 million, according to real-time data from InvestingPro, which gives an idea of ​​the company's size and scope in the biopharmaceutical industry.

Despite TERN-701's potential, InvestingPro Tips indicates that the company is not expected to be profitable this year, with analysts noting that the company has not paid a dividend to shareholders and that the stock has trended against the market trend. The company's rapid cash burn and weak gross margins are areas of concern for investors. On the bright side, Tuozhen Pharmaceuticals does have more cash than debt on its balance sheet, and its liquid assets exceed short-term debt, providing some financial stability while it continues to invest in research and development.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads

InvestingPro's key data metrics show that the price-to-earnings ratio (adjusted for the trailing twelve months to Q4 2023) is -3.64 and the price-to-book ratio is 1.29. The company's shares fell 25.15% last month, reflecting market challenges. However, the numbers provide a nuanced picture of Tuozhen's financial prospects as clinical trials progress.

For investors who would like a deeper understanding of Terns Pharmaceuticals' financials and forecasts, additional InvestingPro tips are available at https://www.investing.com/pro/TERN.Use coupon code PRONEWS24 Enjoy an additional 10% off with annual or annual Pro and Pro+ subscriptions, which include access to a comprehensive set of indicators and expert analysis to inform investment decisions.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *